Facultad de Medicina (FM)
Centro académico
University of Calgary
Calgary, CanadáPublicacións en colaboración con investigadores/as de University of Calgary (34)
2024
-
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457
-
Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries
Heart and Lung, Vol. 68, pp. 131-144
2023
-
An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)
Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516
2022
-
Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis
Critical Care, Vol. 26, Núm. 1
-
Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis
Journal of Hepatology, Vol. 77, Núm. 1, pp. 98-107
-
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Blood, Vol. 139, Núm. 6, pp. 835-844
-
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501
2021
-
Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET
Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820
-
Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C
Journal of Clinical Endocrinology and Metabolism, Vol. 106, Núm. 2, pp. E660-E674
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2020
-
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
Blood Advances, Vol. 4, Núm. 23, pp. 5988-5999
-
Pallium Canada's Curriculum Development Model: A Framework to Support Large-Scale Courseware Development and Deployment
Journal of Palliative Medicine, Vol. 23, Núm. 6, pp. 759-766
2019
-
Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, pp. 301-309
2018
-
Safety and dose modification for patients receiving niraparib
Annals of Oncology, Vol. 29, Núm. 8, pp. 1784-1792
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2014
-
Clinical practice guidelines for delirium management: Potential application in palliative care
Journal of Pain and Symptom Management, Vol. 48, Núm. 2, pp. 249-258
2013
-
Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
Clinical Breast Cancer, Vol. 13, Núm. 6, pp. 421-432.e8
2011
-
Establishing a multicenter clinical research network: Lessons learned
Current Oncology, Vol. 18, Núm. 5